Business
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis Improvements across all patient reported outcomes (PROs) were observed from baseline to Week 8 in all PRO instruments utilized in the ABTECT induction trials evaluating bowel urgency, sleep interruption, fatigue, quality of life, and work productivity for both 50mg and 25m
About this update from Abivax Sa
[{"type":"image","alt":"Abivax","displaySize":"","headline":null,"caption":"Abivax","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/0044215fa29748cca33ccfeb49550e73"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/v57CPS2C3Q2FJGKeA0P43g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/0044215fa29748cca33ccfeb49550e73","width":300,"height":44}},"lazy":false},{"type":"text","content":"Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis ","length":226,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Improvements across all patient reported outcomes (PROs) were observed from baseline to Week 8 in all PRO instruments utilized in the ABTECT induction trials evaluating bowel urgency, sleep interruption, fatigue, quality of life, and work productivity for both 50mg and 25mg once-daily obefazimod.","length":297,"tagName":"p"}]},{"val":[{"type":"text","content":"At week 8 in the ABTECT 1 & 2 trials, 37% of patients taking once daily 50mg obefazimod reported no bowel urgency (BU) compared to 18.1% of patients in the placebo group (18.9, p<0.00011), with improvements in BU observed as early as week two","length":249,"tagName":"p"}]},{"val":[{"type":"text","content":"47.6% of patients on 50mg obefazimod reported no nocturnal bowel movements (NBM) at week 8 compared to 24.7% in the placebo group (23.1, p<0.00011)","length":150,"tagName":"p"}]},{"val":[{"type":"text","content":"In the 50 mg group 17.1% of patients reported fatigue remission as measured with the Fatigue Numerical Rating Scale (NRS) at week 8, compared to 7.7% in the placebo group ( 9.5, p=0.00011)","length":188,"tagName":"p"}]},{"val":[{"type":"text","content":"Detailed data across PROs, including data for both 25mg and 50mg groups, to be submitted for presentation at upcoming medical meetings","length":134,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1018,"olType":false},{"type":"text","content":"PARIS, France – November 3, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a cli...